• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Diamedica Therapeutics Inc (NQ: DMAC )

    4.040 +0.090 (+2.28%)
    Streaming Delayed Price Updated: 10:40 AM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,847
    Open 4.000
    Bid (Size) 4.000 (1)
    Ask (Size) 4.040 (1)
    Prev. Close 3.950
    Today's Range 3.935 - 4.040
    52wk Range 1.938 - 4.070
    Shares Outstanding 37,953,711
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
    DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire

    Performance

    YTD
    +42.76%
    +42.76%
    1 Month
    +7.73%
    +7.73%
    3 Month
    +41.75%
    +41.75%
    6 Month
    +36.03%
    +36.03%
    1 Year
    +38.83%
    +38.83%

    More News

    Read More
    DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Recap: DiaMedica Therapeutics Q4 Earnings
    Via Benzinga
    Earnings Outlook For DiaMedica Therapeutics
    Via Benzinga
    DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces $11.8 Million Private Placement
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
    Via InvestorPlace
    DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Earnings Scheduled For November 13, 2023
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.